StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The deal provides tangible growth leverage through apogee’s candidates and a potential earnings kicker in 2032, plus near-term premium for Apogee; typical M&A uplift is expected, though full accretion visibility hinges on integration and milestone execution.
What happened, with direct paths to the underlying reporting
AbbVie is buying Apogee Therapeutics for $135.11 per share in cash, with close anticipated in Q3 2026, expanding its immunology and respiratory portfolio with APG777 (zumilokibart) and APG273/333 for asthma. The deal is expected to be earnings-accretive from 2032 and includes Ayvakit/avapritinib, enhancing long-term growth potential via a broader pipeline.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.